Ethical considerations

The conduct of clinical research involving children raises profound ethical questions that go beyond those encountered in adult trials. Children are recognized as a vulnerable population in research ethics frameworks, primarily because they lack full and individual decision-making capacity and are therefore unable to provide independent informed consent. This places a heightened duty of care on researchers, sponsors, ethics committees and regulators to ensure that paediatric trials are conducted to the highest ethical standards and children’s rights are considered throughout study conduct. 

Ethical frameworks recognizing children as a vulnerable group

The foundational ethical principles governing clinical research – respect for people, beneficence and justice – are articulated in the Belmont Report and have been elaborated for paediatric research in subsequent international frameworks (Fig. 1). The 2024 Declaration of Helsinki provides the cornerstone ethical framework for all human medical research and includes specific provisions relating to vulnerable populations, including children. A new provision recognizes that default exclusion of all people in positions of vulnerability had resulted in gaps in knowledge about populations, exacerbating disparities in medical research. This is especially true when children are excluded from research on diseases that only affect children. 

Contemporary ethical frameworks acknowledge that exclusion from research is itself unethical – children have a right to benefit from participating in clinical trials and any new evidence base that research generates. This therapeutic orphan problem has driven major regulatory and policy reforms over the past two decades, including the guidelines of the Council for International Organizations of Medical Sciences for health-related research involving humans, which further addresses research ethics in children by detailing the provisions for involving vulnerable groups. 

Key ethical requirements specific to paediatric research include: 

  • the requirement for a favourable risk–benefit assessment;
  • the use of age-appropriate informed consent from children who have sufficient understanding;
  • the requirement for parental or guardian consent;
  • minimizing pain, distress and invasive procedures; and
  • independent ethical review by committees with paediatric expertise.

Fig. 1. International ethical and regulatory frameworks for paediatric clinical research

Conventions
 
  • United Nations – Convention of the Rights of the Child (1989)
  • Council of Europe – Convention on Human Rights and Biomedicine ETS 164 (1997)
  • U.S. HHS – The Common Rule (45 CFR 46)
Declarations
 
  • United Nations – Universal Declaration of Human Rights (1948)
  • World Medical Association – Declaration of Helsinki, DoH (1964; 2025)
  • UNESCO – Universal Declaration on Bioethics and Human Rights (2005)
Guidelines
 
  • ICH – Good Clinical Practice; E6 (1996, Addendum E6; R3 2025)
  • ICH – Clinical investigation of medicinal products in pediatric populations; E11 (2000, R1 2017, E11A 2024)
  • CIOMS – International Ethical Guidelines for Health-related Research Involving Humans (2016)
  • FDA – Ethical considerations for clinical investigations of medical products involving children. Draft guidance for comment purposes (2022)
Legal texts & regulatory statements
 
  • EU – Clinical Trial Regulation (2014)
  • EU – Pediatric Regulation (2006); currently under revision
  • U.S. HHS – Belmont Report (1978), Subpart D – Additional Protections for Children Involved as Subjects in Research
  • U.S. FDA 21 CFR 50, 56, 312

Source: adapted from: Chapter 17: Ethical consideration in the design and conduct of pediatric clinical trials (https://www.sciencedirect.com/science/chapter/edited-volume/abs/pii/B9780323884594000171#article).


Key resources

Independent ethical review of paediatric clinical trials

All clinical research involving children must receive independent ethical review and approval before any participant is enrolled. Ethical review committees – variously termed institutional review boards (institutional review boards), ethics committees or research ethics committees depending on the jurisdiction – are responsible for assessing whether a proposed paediatric trial is scientifically sound, ethically justified and adequately protects the rights, safety and well-being of child participants. 

In paediatric trials, this review is more demanding than for equivalent adult studies, and ethics committees must apply additional scrutiny to several specific areas: 

  • scientific justification for involving children in the study rather than adults; 
  • risk–benefit assessment, including whether the risks posed to children are minimized and are proportionate to the anticipated benefits; 
  • the age-appropriateness of the investigational product’s formulation and dose; 
  • the adequacy of the consent and assent processes, including the materials to be used and the age thresholds applied; and 
  • the plan for minimizing the burden from study procedures, including blood sampling volumes; and the arrangements for ongoing safety monitoring, including data safety monitoring board composition and stopping rules. 

Ethics committees reviewing paediatric protocols should ideally include members with relevant paediatric clinical expertise or should seek specialist paediatric advice when this expertise is not available within the standing membership. In multinational trials, the ethical review requirements of every country in which the trial is conducted must be met, and approval in one jurisdiction satisfying the requirements of another cannot be assumed. Many national regulatory frameworks – including European Union (EU) Clinical Trials Regulation 536/2014 and the United States federal policy for the protection of human subjects (45 CFR 46 Subpart D) – contain specific provisions governing the ethical review of research involving children, and both the research team and the reviewing committee must understand and apply these. 

Background resources

Informed consent and assent

Obtaining and maintaining informed consent from parents or legal guardians and meaningful assent from children with sufficient understanding are cornerstones of ethical paediatric research. The consent and assent process in paediatric trials must be carefully designed to meet the needs of children and families at different developmental stages. 

Parental or guardian consent must be obtained before any study procedures are conducted. Consent information should be presented in plain language, free from jargon and at an appropriate reading level. Information should cover: the purpose and nature of the research; what participation involves; the risks and potential benefits; the right to withdraw at any time without consequence; how data and samples will be stored and used; and who to contact with questions or concerns. Adequate time must be allowed for families to consider the information, ask questions and discuss with others before deciding. 

Assent is a child’s affirmative agreement to participate in research. Assent should be sought from children who have sufficient understanding and maturity to meaningfully engage with the decision. The age of assent varies by context, developmental level and national laws, and local ethics committees should therefore be consulted when the protocol is being developed. Assent materials should use age-appropriate language, pictures and formats and should explain the research in terms children can understand. The refusal of assent by a child should be respected unless the research offers direct clinical benefit and there is no reasonable alternative. There is no international fixed age of assent, so national and institutional guidelines on assent age thresholds and processes should always be consulted. 

Research without prior consent in biomedical research is used in situations where treatment must be immediate in the case of an emergency or when the research offers a potentially life-saving intervention needed urgently. This is especially relevant in neonatal research or when a child is critically ill. This is a practical approach that administers trial interventions immediately during an emergency to eligible people and then consent for ongoing involvement in the study is sought after the emergency has passed.

Key resources